



**HAL**  
open science

## Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations

Philippe Jamme, Marie Fernandes, Marie-Christine Copin, Clotilde Descarpentries, Fabienne Escande, Angela Morabito, Valérie Grégoire, Matthieu Jamme, Simon Baldacci, David Tulasne, et al.

### ► To cite this version:

Philippe Jamme, Marie Fernandes, Marie-Christine Copin, Clotilde Descarpentries, Fabienne Escande, et al.. Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations. *Journal of Thoracic Oncology*, 2020, 15, pp.741 - 751. 10.1016/j.jtho.2020.01.027 . hal-03490340

**HAL Id: hal-03490340**

**<https://hal.science/hal-03490340>**

Submitted on 22 Aug 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1 **Title**

2 Alterations in the PI3K pathway drive resistance to MET inhibitors in NSCLC  
3 harboring MET exon 14 skipping mutations

4 **Short title**

5 PI3K pathway alterations drive resistance to MET TKIs in METex14 NSCLC

6 **Authors**

7 Philippe Jamme 1, Marie Fernandes 1, Marie-Christine Copin 1,2, Clotilde  
8 Descarpentries 3, Fabienne Escande 3, Angela Morabito 1, Valérie Grégoire 2,  
9 Matthieu Jamme 4, Simon Baldacci 5, David Tulasne 1, Zoulika Kherrouche 1, and  
10 Alexis B. Cortot 1,5.

11 **Affiliations**

- 12 **1. Univ. Lille, CNRS, Institut Pasteur de Lille, UMR 8161 - M3T - Mechanisms of**  
13 **Tumorigenesis and Targeted Therapies, F-59000 Lille, France**
- 14 **2. Univ. Lille, Institut de Pathologie, CHU Lille, Avenue Oscar Lambret, F-59000**  
15 **Lille, France**
- 16 **3. Univ. Lille, Department of Biochemistry and Molecular Biology « Hormonology**  
17 **Metabolism Nutrition Oncology », CHU lille, F-59000, Lille, France**
- 18 **4. INSERM U-1018, CESP, Team 5 (EpReC, Renal and Cardiovascular**  
19 **Epidemiology), UVSQ, Villejuif, France**
- 20 **5. Univ. Lille, Thoracic Oncology Department, CHU Lille, F-59000, France**

21

22

23 **Corresponding author :**

24 Alexis B. Cortot

25 Hôpital Calmette, CHU Lille, Boulevard du Professeur Leclercq

26 59037 Lille, France

27 Tel : +33 3 20 44 49 98 / Fax : +33 3 20 44 56 11

28 Email : alexis.cortot@chru-lille.fr

29 **Key Words** : TKI, Resistance, MET, PI3K, NSCLC

### 30 **Disclosure of fundings**

31 ABC participated in advisory boards or received honoraria from Astra-Zeneca,  
32 Bristol-Myers Squibb, Merck & Co, Pfizer, Roche, Novartis, Takeda, and received  
33 grants payed to ABC's institution from Novartis, Merck.

34 Dr. Jamme reports non-financial support from Chugai Pharma, personal fees from  
35 Boehringer Ingelheim , non-financial support from Roche, non-financial support from  
36 BMS, outside the submitted work .

37 SB reports personal fees and non-financial support from Lilly, GSK, Roche, and  
38 Pfizer, a grant from the Intergroupe Francophone de Cancérologie Thoracique  
39 outside the submitted work.

40 MCC participates in advisory boards for Pfizer and Roche.

41 CD reports personal fees and non-financial support from AstraZeneca, Novartis  
42 pharma SAS, Roche SAS, Boehringer Ingelheim France, Pfizer, outside the  
43 submitted work

44 VG, ZK, AM, DT, MF, and FE have no conflicts of interest.

45

46

47

48

49

50 Abstract

51 **Introduction**

52 MET TKIs (tyrosine kinase inhibitors) have demonstrated efficacy against advanced  
53 NSCLC with mutations causing MET exon 14 skipping (*METex14* mutations), but  
54 primary resistance seems frequent, as response rates are lower than for targeted  
55 TKIs of other oncogene-addicted NSCLC. Given the known interplay between MET  
56 and PI3K, we hypothesized that in *METex14* NSCLC, PI3K-pathway alterations might  
57 contribute to primary resistance to MET TKIs.

58 **Methods**

59 We reviewed clinical data from 65 patients with *METex14* NSCLC, assessing PI3K-  
60 pathway alterations by targeted NGS (mutations) and immunohistochemistry (loss of  
61 PTEN). Using a cell line derived from a patient with primary resistance to a MET TKI  
62 and cell lines harboring both a *METex14* mutation and a PI3K-pathway alteration, we  
63 assessed sensitivity to MET TKIs used alone or with a PI3K inhibitor and investigated  
64 relevant signaling pathways.

65 **Results**

66 We found a *PIK3CA* mutation in 2/65 samples (3%) and loss of PTEN in 6/26 (23%).  
67 All three of the MET-TKI-treated patients with a PI3K pathway alteration had shown  
68 progressive disease at first assessment. Likewise, MET TKIs had no effect on the  
69 proliferation of *METex14*-mutated cell lines with a PI3K-pathway alteration, including

70 the PTEN-lacking patient-derived cell line. Treatment combining a MET TKI with a  
71 PI3K inhibitor caused inhibition of both PI3K and MAPK signaling and restored  
72 sensitivity to MET TKIs.

### 73 **Conclusion**

74 PI3K-pathway alterations are common in *MET*<sup>ex14</sup> NSCLC and may confer primary  
75 resistance to MET TKIs. In preclinical models, PI3K inhibition restores sensitivity to  
76 MET TKIs.

77

78 **Introduction**

79 Splice site mutations located in the regions flanking exon 14 of the MET oncogene  
80 (*METex14*) have been reported in 3% of patients with non-small cell lung cancer  
81 (NSCLC) <sup>1,2</sup>. Elderly persons and smokers constitute a larger proportion of patients  
82 harboring these mutations than of patients with alterations affecting other key  
83 oncogene drivers such as EGFR or ALK<sup>3</sup>. *MET* exon 14 skipping, causing the  
84 absence of the MET juxtamembrane domain (containing several negative regulation  
85 sites), leads to increased MET receptor stability and activation<sup>4</sup>. This activation  
86 results in recruitment of effector proteins such as GAB1, GRB2, SHC, STAT, and  
87 PI3K, leading to activation of downstream signaling pathways including the PI3K,  
88 MAPKinase, and JAK-STAT pathways <sup>4,5</sup>. As *METex14* mutations can confer  
89 sensitivity to MET inhibition, several clinical trials have evaluated MET tyrosine  
90 kinase inhibitors (TKIs) in *METex14* NSCLC. Reported objective response rates  
91 (ORRs) range from 32% to 67.9% <sup>6-9</sup>. These results are somewhat lower than  
92 observed with targeted therapies for other oncogene-addicted NSCLC, such as  
93 *EGFR*-mutated or *ALK*-rearranged NSCLC. This may be due to a higher frequency of  
94 primary resistance mechanisms in *METex14* NSCLC, including concurrent molecular  
95 alterations.

96 The PI3K signaling pathway is involved in several cell functions induced by activation  
97 of the MET receptor, including cell migration and survival<sup>10</sup>. The MET receptor  
98 interacts with class I PI3K isoforms directly through their SH2 domain and indirectly  
99 through activation of GAB1, FAK, and RAS<sup>10</sup>. PI3K promotes phosphorylation of  
100 PIP2 to PIP3, favoring plasma membrane recruitment of the PDK1 kinase, leading  
101 notably to AKT phosphorylation. The PTEN phosphatase (Phosphatase and TENsin  
102 homolog), on the other hand, causes PIP3 dephosphorylation and thus acts as the

103 main regulator of the PI3K pathway. The PI3K pathway is frequently dysregulated in  
104 NSCLC. *PIK3CA* and *AKT1* mutations are found, respectively, in 4.1-5.2%<sup>11-13</sup> and  
105 0.2-1.9%<sup>14-16</sup> of lung cancers, and loss of PTEN has been reported in 24% of  
106 NSCLC. Several papers report the role of PI3K pathway alterations in resistance to  
107 cancer therapy, including TKI treatment<sup>17,18</sup>. Given the role of the MET receptor in  
108 direct activation of the PI3K pathway, we hypothesized that alterations in this  
109 pathway might contribute to the resistance of *METex14* NSCLC to MET inhibitors.

110

## 111 **Results**

### 112 **PI3K pathway alterations are common in *METex14* NSCLC**

113 Considering the involvement of the PI3K pathway in resistance to TKIs in several  
114 oncogene-addicted cancer models, we focused retrospectively on PI3K-pathway  
115 alterations in a multicentric cohort of NSCLC patients whose tumors displayed  
116 *METex14* mutations. All tumor samples were obtained at diagnosis, before any  
117 systemic treatment. Screening for mutations had been done using the CLAPv1  
118 optimized next-generation sequencing (NGS) panel combined with fragment length  
119 analysis, as previously described<sup>2</sup>. All these mutations were previously described or  
120 predicted to induce MET exon14 skipping (**Table S1**). The median age was 75.0  
121 years (range 49-88); there were as many men as women (49%) and as many  
122 smokers as never-smokers (55%). Most patients had been diagnosed at an  
123 advanced stage (67%). Seventeen of them had received a MET TKI, either off-label  
124 or as part of a clinical trial (**Figure 1A**).

125 The *METex14* mutations detected in this cohort were of the following types: deletions  
126 in 30 patients (46%), substitutions in 28 patients (42%), and indels in 7 patients

127 (12%). Thirty-nine samples had been tested for *MET* gene amplification by FISH, of  
128 which 5 (13%) were positive: one with low amplification (*MET/CEP7* ratio 1.8), one  
129 with intermediate amplification (*MET/CEP7* ratio 3.2), and three with high  
130 amplification (clusters in 53-78% of tumor cells) (**Table S1**).

131 Samples from all 65 patients had been tested for PI3K pathway alterations (*PIK3CA*,  
132 *AKT*, and *PTEN* mutations) by targeted NGS, revealing two *PIK3CA* mutations (3%)  
133 (**Figure 1B**) but no *AKT* or *PTEN* mutation. We further evaluated *PTEN* expression  
134 by immunohistochemistry (IHC) performed on 26 available tumor samples (**Table**  
135 **S3**). This revealed 6 samples (23%) with total loss of *PTEN* expression (**Figure 1C**  
136 **and S1**).

137 In addition to the above, the observed mutations included 15 *TP53* mutations (27%),  
138 two *KRAS* mutations (G13C), one *NRAS* mutation (Q61L), one *EGFR* mutation  
139 (V774M), and one *SMAD4* mutation (D351N) (**Table S1**). Overall, six of the 26  
140 samples tested by both NGS and *PTEN* IHC (23%) displayed a PI3K-pathway  
141 alteration. This makes the PI3K pathway one of the most altered pathways in  
142 *METex14* NSCLC.

143 **METex14 patients with concurrent alterations in the PI3K pathway display**  
144 **primary resistance to MET TKIs**

145 To determine whether PI3K-pathway alterations might impact sensitivity to *MET*  
146 inhibition, we analyzed responses to treatment in the 17 *METex14* NSCLC patients  
147 having received a *MET* TKI.

148 Tumor samples from three of these patients appeared, on the basis of either NGS or  
149 *PTEN* IHC, to have an impaired PI3K pathway (**Figure 1D**).



150 In 14 patients, no alteration of the PI3K pathway was detected. This means that NGS  
151 revealed no *PIK3CA*, *AKT*, or *PTEN* mutation and that the corresponding tumor  
152 samples were either PTEN positive (4 samples) or had not been analyzed by PTEN  
153 IHC (10 samples). Of these 14 patients, nine displayed an objective response (64%),  
154 one achieved disease stability for six months, and four showed progressive disease  
155 at first assessment. Although none of these last four harbored a *PIK3CA* mutation,  
156 one of them, identified as PTEN-positive, harbored an *EGFR* V774M mutation likely  
157 to explain primary resistance to MET TKI. The PTEN status of the other three was  
158 not available. The three PTEN-positive patients with no *EGFR*, *KRAS*, or *TP53*  
159 mutation all responded to MET TKI treatment.

160 In contrast, all three patients with an impaired PI3K pathway, including one with a  
161 *PIK3CA* mutation and two with total loss of PTEN expression, showed progressive  
162 disease at first radiological assessment (**Figure 1 D, E**). The clinical courses of these  
163 three patients are detailed below.

164 Patient CHUL#11, harboring a c.3082+1G>T MET mutation, was a 49-year-old  
165 former-smoker woman diagnosed with stage IV NSCLC. She received first-line  
166 platinum-based chemotherapy, but progression was observed after four cycles of  
167 treatment. The patient then received a MET TKI as part of a clinical trial. Treatment  
168 was stopped at first radiological assessment because of rapid disease progression  
169 (**Figure 1E**). The patient further received an anti-PD1 agent followed by a new  
170 course of chemotherapy with no efficacy. She died nine months after diagnosis.  
171 PTEN IHC performed on a right cervical lymph node obtained before treatment with  
172 the MET TKI revealed loss of PTEN expression (**Figure 1C**).

173 Patient CHUL#18, harboring a c.3067\_3082+1delinsC MET mutation, was a 75-year-  
174 old woman diagnosed with advanced adenocarcinoma. She received six cycles of  
175 platinum-based chemotherapy with maintenance pemetrexed for one year. She then  
176 received a MET TKI as part of a clinical trial. The treatment was stopped at first  
177 radiological assessment because of new bone and adrenal gland metastases  
178 (**Figure 1E**). The patient died three months later. PTEN IHC performed on a  
179 pretreatment bronchial biopsy revealed loss of PTEN expression (**Figure S1**).

180 Patient CHUL#20 harboring a c.3082+1G>A MET mutation was a 75-year-old  
181 woman diagnosed with metastatic pulmonary sarcomatoid carcinoma. The patient  
182 was not eligible for chemotherapy and therefore received a MET TKI as first-line  
183 therapy. The treatment was stopped at first radiological assessment because of  
184 lymph node progression (**Figure 1E**). The patient died within two weeks after  
185 discontinuing treatment. Targeted NGS performed on the lung tumor revealed an  
186 activating *PIK3CA* mutation (N1044K).

187 These three cases suggest that in METex14 NSCLC patients, alterations in the PI3K  
188 pathway are associated with primary resistance to MET TKIs.

189 **PTEN loss is associated with sustained activation of the PI3K pathway and**  
190 **resistance to MET TKIs in METex14 cancer cells**

191 To decipher the role of PI3K-pathway alterations in resistance to MET TKIs, we  
192 derived a cell line from a pleural effusion sample from patient CHUL#11, collected at  
193 progression on third-line therapy. The tumor sample from this patient harbored a  
194 *METex14* mutation and displayed no PTEN expression detectable by IHC (**Figure**  
195 **1C**). Targeted NGS confirmed in this cell line (named ZORG) the presence of the  
196 *METex14* mutation c.3082+1G>T, identical to that found in the patient tumor sample.

197 As expected, the mutation leads to exon 14 skipping, as validated by fluorescence  
198 RT-PCR with primers located in MET exons 13 and 15. As shown in **Figure 2A**, the  
199 amplicon amplified from ZORG cells migrated as expected to 128 bp, as observed  
200 with cell lines known to harbor *METex14* mutations (Hs746T and H596). The  
201 amplicons from MET wild-type cell lines (A549, PC9, and GTL16) migrated to 286 bp.  
202 In addition, the dissociation temperature of the amplicon from ZORG cells (74.8°C)  
203 was in agreement with that of MET lacking exon 14. Finally, western blotting revealed  
204 a lack of PTEN in ZORG cells (**Figure 2B**).

205 MET expression and downstream signaling were investigated by western blotting in  
206 ZORG cells stimulated or not by the MET ligand HGF (Hepatocyte Growth Factor).  
207 As shown in **Figure 2C**, unstimulated *METex14* and ERK displayed no  
208 phosphorylation, while HGF stimulation induced MET phosphorylation and  
209 subsequent activation of ERK. In contrast, as an expected consequence of PTEN  
210 loss, AKT was activated by its ligand even in the absence of MET activation.  
211 Stimulation by HGF led to overactivation of the PI3K pathway. All further experiments  
212 were performed under HGF supplementation.

213 The sensitivity of ZORG cells to MET TKIs was then analyzed in viability assays  
214 using MTT. Four MET TKIs (the type-I inhibitors crizotinib, capmatinib, and tepotinib  
215 and the type-II inhibitor foretinib) were tested at increasing doses. The viability of  
216 ZORG cells was practically unaffected by capmatinib or tepotinib at doses as high as  
217 10  $\mu$ M Crizotinib (a multitarget inhibitor of MET, ROS, and ALK) and foretinib  
218 displayed low viability-reducing activity on ZORG cells, with a half-maximal inhibitory  
219 concentration (IC<sub>50</sub>) above 1  $\mu$ M following a 72-h exposure to the drug. By  
220 comparison, all four TKIs reduced the viability of Hs746T cells, known to harbor both  
221 *METex14* mutation and amplification, with an IC<sub>50</sub> below 0.1  $\mu$ M (**Figure 2D**).

222 Investigation of signaling pathways by western blotting showed all four MET TKIs to  
223 inhibit MET phosphorylation in both ZORG and Hs746T cells. MET TKIs nearly  
224 abolished both AKT and ERK phosphorylation in Hs746T cells, but had little effect in  
225 ZORG cells (**Figure 2E**). Overall, these results suggest that PTEN loss is associated  
226 with resistance to type-I and type-II MET TKIs in *METex14* cells through sustained  
227 activation of the PI3K pathway.

228

### 229 **Inhibition of PI3K restores sensitivity to MET TKIs in *METex14* cells showing** 230 **PTEN loss**

231 To further demonstrate the role of PI3K-pathway alterations in resistance to MET  
232 TKIs, we tested whether PI3K inhibition might restore sensitivity of ZORG cells to  
233 MET TKIs. Proliferation of ZORG cells was unaffected by treatment with capmatinib,  
234 one of the most selective and potent MET TKIs<sup>19</sup>, and was only slightly slowed down  
235 by GDC0941, a specific inhibitor of PI3K $\alpha/\delta$  (**Figure 3A**). When these two inhibitors  
236 were combined, however, proliferation of ZORG cells was significantly reduced. The  
237 same inhibitor combination had no effect on cell lines with no MET alteration, such as  
238 A549 (*KRAS* G12S mutation) and PC9 (EGFR E746-A750 deletion). For ZORG cells,  
239 the IC<sub>50</sub> for capmatinib shifted from over 10  $\mu$ M, when the inhibitor was used alone,  
240 to 0.034  $\mu$ M, when it was used in combination with GDC0941 (1 $\mu$ M) (**Figure 3B**).

241 Analysis of the downstream signaling pathway revealed that capmatinib or GDC0941  
242 added alone only slightly reduced the phosphorylation levels of ERK and AKT,  
243 whereas the combination of both inhibitors fully abolished AKT activation and  
244 drastically inhibited ERK activation (**Figure 3C**). Overall, these results demonstrate  
245 that ZORG cells, which display both a *METex14* mutation and PTEN loss, rely on

246 both the PI3K and MET pathways for cell growth, and that combining a MET inhibitor  
247 with a PI3K inhibitor is required to achieve cell growth arrest.

248

249 **Inhibition of PI3K restores sensitivity to MET TKIs in *METex14* cells displaying**  
250 **a *PIK3CA* mutation**

251 Given the action of the PI3K-MET inhibitor combination on *METex14* cells with  
252 concurrent PTEN loss, we investigated whether the same is true when PI3K  
253 activation is due to a *PIK3CA* mutation. For this we used the lung adenocarcinoma  
254 cell line H596, known to harbor the activating E545K *PIK3CA* mutation along with a  
255 *METex14* mutation.

256 We first confirmed in a viability assay that H596 cells are resistant to crizotinib, as  
257 previously shown<sup>5</sup>, and to the MET TKIs capmatinib, tepotinib, and foretinib (**Figure**  
258 **4A**). We then studied the effect of MET and PI3K inhibitors, added alone or in  
259 combination, on cell growth. Like that of ZORG cells, H596 cell proliferation was  
260 unaffected by capmatinib alone. It was slowed down in the presence of GDC0941  
261 alone. In the presence of both inhibitors combined, full cell growth arrest was  
262 achieved (**Figure 4B**).

263 Signaling pathway analysis revealed only a slight effect of capmatinib on AKT and  
264 ERK activation. When the MET and PI3K inhibitors were combined, the levels of both  
265 phospho-AKT and phospho-ERK decreased markedly (**Figure 4C**). For H596 cells,  
266 the IC<sub>50</sub> for capmatinib shifted from over 10  $\mu$ M, when the inhibitor was used alone,  
267 to 0.06  $\mu$ M, when it was used in combination with GDC0941 (**Figure 4D**). Taken  
268 together, these results demonstrate that inhibition of both MET and PI3K is required

269 to achieve full cell growth arrest and to suppress activation of the PI3K and  
270 MAPKinase pathways in *METex14* cells harboring a concurrent *PIK3CA* mutation.

271

272 ***METex14* mutations contribute to resistance to PI3K inhibition in *PIK3CA*-**  
273 **mutated cells**

274 Since PI3K-pathway alterations confer resistance to MET TKIs in *METex14* cells, we  
275 investigated whether *METex14* mutations might similarly confer resistance to a PI3K  
276 inhibitor in *PIK3CA*-mutated cells.

277 For this purpose, we chose the epithelial cell line T47D, harboring a H1047F-  
278 activating *PIK3CA* mutation and expressing low levels of endogenous MET. To  
279 observe the specific effect of *METex14* on the biological responses of such cells, we  
280 created the T47DMETex14 cell line by stable transfection with a vector expressing a  
281 mutant MET (*METex14*, c. 2887\_3028del).

282 First we confirmed the presence of the exogenous *METex14* in the T47DMETex14  
283 cells and its absence in the parental T47D cells (**Figure S2A**). We then evaluated the  
284 sensitivity of these cells to MET TKIs. We found both T47D and T47DMETex14 cells  
285 to be resistant to all tested MET TKIs (**Figure S2B**).

286 We further studied the effect of MET and PI3K inhibitors, alone and in combination,  
287 on cell proliferation. In T47D cells, we found GDC0941 alone to suppress cell growth.  
288 Adding capmatinib had no additional impact. Proliferation of these cells thus appears  
289 to depend strictly on the PI3K pathway (**Figure 5A**). In contrast, treating  
290 T47DMETex14 cells with GDC0941 only slowed down cell growth. Capmatinib alone  
291 slightly increased cell growth. To achieve full cell growth arrest, combining GDC0941

292 with capmatinib was required. This suggests that proliferation of these cells relies on  
293 both the PI3K and MET pathways.

294 Analysis of the signaling pathways revealed that PI3K activation depends partly on  
295 MET activation in T47DMETex14 cells but not in T47D cells. ERK activation was  
296 found to depend strictly on MET activation. It proved necessary to combine MET and  
297 PI3K inhibitors to fully inhibit both AKT and ERK activation (**Figure 5B**). For  
298 T47DMETex14 cells, the IC50 for capmatinib shifted from over 10  $\mu$ M, when the  
299 inhibitor was used alone, to 0.007  $\mu$ M, when it was used in combination with  
300 GDC0941 (**Figure 5C**).

301 Taken together, these results demonstrate that *METex14* can induce MET addiction  
302 even in the presence of a concurrent oncogene mutation such as a *PIK3CA*  
303 mutation, and that this leads to resistance to a MET or PI3K inhibitor used alone.  
304 Combined inhibition thus appears required in the case of concurrent alterations  
305 activating MET and a second signaling pathway.

306

## 307 **Discussion**

308 *METex14* mutations define a new subgroup of NSCLC patients who may benefit from  
309 targeted therapies against MET. Several MET TKIs have demonstrated efficacy in  
310 ongoing clinical trials for patients with *METex14* NSCLC, with a 32-67.9% ORR rate  
311 and a 7.3-10.8 months median PFS<sup>6-9</sup>. Yet the observed ORR rate is lower than for  
312 TKI treatment of EGFR-mutated or ALK-rearranged NSCLC, usually found to be 70-  
313 80%. Accordingly, the proportion of *METex14* NSCLC patients showing progressive  
314 disease as best response to MET TKIs ranged up to 32%<sup>6-9</sup>, suggesting that these  
315 cancers are not driven by MET-dependent mechanisms only.

316 Primary resistance of oncogene-addicted cancers to targeted therapies may have  
317 several causes, including concurrent genomic alterations<sup>20</sup>. In the present study,  
318 based on a cohort of 65 *METex14* NSCLC patients, we find that alterations in the  
319 PI3K pathway, including PTEN loss and *PIK3CA* mutations, are common and can be  
320 associated with resistance to MET TKIs. We confirm here, using a patient-derived  
321 cell line combining a *METex14* mutation with PTEN loss, that PI3K-pathway  
322 alterations confer resistance to type-I and type-II MET TKIs. Importantly, we show  
323 that adding a PI3K inhibitor to the treatment can restore sensitivity of these cells to  
324 the MET TKI. Similar results are obtained with *METex14* cells harboring a concurrent  
325 *PIK3CA* mutation. Overall, our data suggest that alteration of the PI3K pathway is  
326 one of the main mechanisms of primary resistance to MET TKIs in *METex14* NSCLC.

327 The most common PI3K-pathway alteration observed in our cohort was PTEN loss.  
328 PTEN loss has been reported in 8-42.4% of NSCLC patients, but previous studies  
329 have included different populations and used various thresholds for PTEN expression  
330 (stained cells 0%<sup>21</sup>, <10%<sup>22</sup>, or <50% of all cancer cells<sup>23</sup> ). The frequency of PTEN  
331 loss in oncogene-addicted NSCLC is poorly known. PTEN mutations have been  
332 reported in 5% of EGFR-mutated NSCLC <sup>24</sup>, and homozygous deletion of PTEN has  
333 been reported in 1 out of 24 EGFR-mutated NSCLC patients<sup>25</sup>. The wide diversity of  
334 genetic and epigenetic alterations affecting PTEN makes it hard to get a  
335 comprehensive molecular profile of the *PTEN* gene. This explains why IHC has  
336 emerged as an attractive and reliable technique for detecting PTEN loss. Like Soria  
337 et al., we have chosen to define PTEN loss as the total absence of PTEN expression  
338 (0% stained cells). Using this criterion, we found a 23% rate of PTEN loss. One  
339 should note that as IHC misses PTEN mutations leading to loss of function without  
340 loss of expression, the rate of true PTEN loss may be underestimated in our cohort.



341 The functional consequences of PTEN loss on responses to TKIs in oncogene-  
342 addicted cancers are still largely unknown<sup>26</sup>. In patients with EGFR-mutated NSCLC,  
343 PTEN expression is associated with prolonged survival<sup>27</sup>. In *METex14* NSCLC, the  
344 impact of PTEN loss has never been addressed so far. Our results strongly suggest  
345 that PTEN loss contributes to resistance to MET TKIs in *METex14* cancer cells  
346 through sustained activation of the PI3K pathway.

347 *PIK3CA* mutations are found in 4% to 5% of NSCLC<sup>11,12,28</sup> and can occur  
348 concurrently with other oncogenic drivers, such as EGFR and KRAS<sup>29</sup>. EGFR-  
349 mutated NSCLC is the only oncogene-addicted NSCLC in which the impact of  
350 *PIK3CA* mutations on responses to TKIs has been studied, and results remain  
351 controversial. Preclinical data suggest that the *PIK3CA* mutation E545K decreases  
352 sensitivity of EGFR-mutated cells to EGFR TKIs<sup>30</sup>. Moreover, *PIK3CA* mutations  
353 were initially proposed as an acquired mechanism of resistance to EGFR TKI in  
354 EGFR-mutated NSCLC patients<sup>31</sup> and were recently found in 3% of patients showing  
355 disease progression after first-line osimertinib<sup>32</sup>. Yet recent findings indicate that the  
356 *PIK3CA* mutation rate in EGFR-mutated NSCLC patients is similar whether the  
357 patients have been treated with EGFR TKIs or not<sup>33</sup>. This suggests a limited role of  
358 *PIK3CA* mutations in resistance to EGFR TKIs. For patients with EGFR-mutated  
359 NSCLC, Eng et al. report worse overall survival in the presence than in the absence  
360 of a concurrent *PIK3CA* mutation, but these authors observed no significant  
361 difference in objective response rate or time to progression in patients on EGFR TKIs  
362<sup>34</sup>. Our present findings suggest that alterations in the PI3K pathway may be  
363 associated with resistance to MET TKIs, since all the *METex14* NSCLC patients  
364 whose tumors harbored such an alteration showed disease progression as best  
365 response on MET TKIs. The view that alterations of the PI3K pathway are involved in

366 resistance to MET TKIs is further validated by our results obtained with cell lines,  
367 including a patient-derived cell line.

368 Besides PI3K-pathway alterations, other concurrent molecular alterations have been  
369 described in *METex14* NSCLC, including *KRAS* mutation and amplification, *MDM2*  
370 amplification, *TP53* mutation, and *EGFR* mutation. Frampton et al. and Awad et al.  
371 respectively found a concurrent alteration in 100 out of 114 (88%) and 26 out of 28  
372 (92%) *METex14* samples<sup>3,35</sup>. This high frequency of concurrent molecular  
373 aberrations may reflect the higher rate of smokers and elderly patients among  
374 *METex14* NSCLC patients as compared to EGFR-mutated or ALK-rearranged  
375 NSCLC patients. Interestingly, concurrent alterations may also impair the response to  
376 MET TKIs. Recently, *KRAS* mutations were found in 4.4% of *METex14* NSCLC  
377 patients, and most of these mutations were identified before any treatment with MET  
378 TKI<sup>36</sup>. Amplification of wild-type *KRAS* has also been described in *METex14* NSCLC  
379 patients as a mechanism of primary and acquired resistance<sup>36,37</sup>. Thus, extensive  
380 molecular profiling of *METex14* tumors appears important in identifying patients who  
381 may benefit from MET TKIs, and this profiling should include screening for PTEN loss  
382 and *PIK3CA* mutations.

383 We find here that a combination of MET and PI3K inhibitors can inhibit the  
384 proliferation of cells harboring a *METex14* mutation and a concurrent *PIK3CA*  
385 mutation or PTEN loss. As *PIK3CA* mutations and PTEN loss lead to activation of the  
386 PI3K pathway, these results suggest that PI3K pathway alterations cause resistance  
387 to MET TKIs. Interestingly, Bahcall et al. have found that the same combination can  
388 inhibit tumor growth in *METex14* tumors with concurrent wild-type *KRAS*  
389 amplification<sup>37</sup>. Taken together, these results strongly suggest that a combination of  
390 MET and PI3K inhibitors might overcome several mechanisms of resistance to MET

391 TKIs in *METex14* NSCLC. So far in the the clinical setting, the use of panPI3K  
392 inhibitors, either alone or in combination, has been hindered by safety issues <sup>38</sup>. A  
393 phase I study evaluating a combination of capmatinib and buparlisib in adult patients  
394 with recurrent glioblastoma was discontinued because of poor tolerance<sup>39</sup>. Yet more  
395 selective drugs have recently been developed and might offer a better safety profile  
396 with promising activity. This would pave the way for future combinations.

397 In conclusion, although *METex14* mutations are associated with MET TKIs efficacy in  
398 a number of patients, concurrent alterations can frequently occur and may impair the  
399 response to MET inhibition. Our results suggest that PI3K-pathway alterations are  
400 common and should be screened in order to identify patients most likely to benefit  
401 from MET TKIs. Combining MET and PI3K inhibitors could overcome resistances due  
402 to PI3K pathway alterations.

403

#### 404 **Acknowledgments**

405 We thank Laurence Stechly for assistance in the screening of tumor samples by  
406 NGS.

407 This work received financial support from the CNRS, the Institut Pasteur de Lille, The  
408 INSERM, The University of Lille, the Cancéropôle Nord-Ouest, the Agence Nationale  
409 de la Recherche and the Groupe Pasteur Mutualité.

410 We thank the Microscopy-Imaging-Cytometry Facility of the BioImaging Center Lille  
411 (BICeL) Nord-de-France for access to instruments and technical advice.

412

413

414 **Bibliography**

415

- 416 1. Salgia R. MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.  
417 *Mol Cancer Ther.* 2017;16(4):555-565. doi:10.1158/1535-7163.MCT-16-0472
- 418 2. Descarpentries C, Leprêtre F, Escande F, et al. Optimization of Routine Testing for  
419 MET Exon 14 Splice Site Mutations in NSCLC Patients. *J Thorac Oncol.* 2018;13(12).  
420 doi:10.1016/j.jtho.2018.08.2023
- 421 3. Awad MM, Oxnard GR, Jackman DM, et al. MET Exon 14 Mutations in Non–Small-  
422 Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET  
423 Genomic Amplification and c-Met Overexpression. *J Clin Oncol.* 2016;34(7):721-730.  
424 doi:10.1200/JCO.2015.63.4600
- 425 4. Cortot AB, Kherrouche Z, Descarpentries C, et al. Exon 14 Deleted MET Receptor as  
426 a New Biomarker and Target in Cancers. *JNCI J Natl Cancer Inst.* 2017;109(5).  
427 doi:10.1093/jnci/djw262
- 428 5. Liu X, Jia Y, Stoopler MB, et al. Next-Generation Sequencing of Pulmonary  
429 Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.  
430 *J Clin Oncol.* 2016;34(8):794-802. doi:10.1200/JCO.2015.62.0674
- 431 6. Drilon A, Clark J, Weiss J, et al. OA12.02 Updated Antitumor Activity of Crizotinib in  
432 Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer. *J Thorac*  
433 *Oncol.* 2018;13(10):S348. doi:10.1016/j.jtho.2018.08.300
- 434 7. Wolf J, Seto T, Han J-Y, et al. LBA52Results of the GEOMETRY mono-1 phase II  
435 study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with  
436 MET $\Delta$ ex14 mutated advanced non-small cell lung cancer (NSCLC). *Ann Oncol.*  
437 2018;29(suppl\_8). doi:10.1093/annonc/mdy424.090
- 438 8. Felip E, Horn L, Patel JD, et al. Tepotinib in patients with advanced non-small cell lung

- 439 cancer (NSCLC) harboring *MET* exon 14-skipping mutations: Phase II trial. *J Clin*  
440 *Oncol.* 2018;36(15\_suppl):9016-9016. doi:10.1200/JCO.2018.36.15\_suppl.9016
- 441 9. Moro-Sibilot D, Cozic N, Pérol M, et al. OA12.03 Activity of Crizotinib in MET or ROS1  
442 Positive (+) NSCLC: Results of the AcSé Trial. *J Thorac Oncol.* 2018;13(10):S348.  
443 doi:10.1016/j.jtho.2018.08.301
- 444 10. Hervieu A, Kermorgant S. The Role of PI3K in Met Driven Cancer: A Recap. *Front Mol*  
445 *Biosci.* 2018;5:86. doi:10.3389/fmolb.2018.00086
- 446 11. Yamamoto H, Shigematsu H, Nomura M, et al. PIK3CA Mutations and Copy Number  
447 Gains in Human Lung Cancers. *Cancer Res.* 2008;68(17):6913-6921.  
448 doi:10.1158/0008-5472.CAN-07-5084
- 449 12. Ludovini V, Bianconi F, Pistola L, et al. Phosphoinositide-3-Kinase Catalytic Alpha and  
450 KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal  
451 Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-  
452 small Cell Lung Cancer. *J Thorac Oncol.* 2011;6(4):707-715.  
453 doi:10.1097/JTO.0b013e31820a3a6b
- 454 13. Jing C, Mao X, Wang Z, et al. Next-generation sequencing-based detection of  
455 EGFR, KRAS, BRAF, NRAS, PIK3CA, Her2 and TP53 mutations in patients with  
456 non-small cell lung cancer. *Mol Med Rep.* June 2018. doi:10.3892/mmr.2018.9210
- 457 14. Malanga D, Scrima M, De Marco C, et al. Activating E17K mutation in the gene  
458 encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung.  
459 *Cell Cycle.* 2008;7(5):665-669. doi:10.4161/cc.7.5.5485
- 460 15. Do H, Solomon B, Mitchell PL, Fox SB, Dobrovic A. Detection of the transforming  
461 AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. *BMC*  
462 *Res Notes.* 2008;1(1):14. doi:10.1186/1756-0500-1-14
- 463 16. Bleeker FE, Felicioni L, Buttitta F, et al. AKT1E17K in human solid tumours.

- 464 *Oncogene*. 2008;27(42):5648-5650. doi:10.1038/onc.2008.170
- 465 17. Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. EGFR-TKIs resistance via EGFR-  
466 independent signaling pathways. *Mol Cancer*. 2018;17(1):53. doi:10.1186/s12943-  
467 018-0793-1
- 468 18. Pons-Tostivint E, Thibault B, Guillermet-Guibert J. Targeting PI3K Signaling in  
469 Combination Cancer Therapy. *Trends in Cancer*. 2017;3(6):454-469.  
470 doi:10.1016/j.trecan.2017.04.002
- 471 19. Baltschukat S, Schacher Engstler B, Huang A, et al. Capmatinib (INC280) Is Active  
472 Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined  
473 Mechanisms of *MET* Activation. *Clin Cancer Res*. January 2019:clincanres.2814.2018.  
474 doi:10.1158/1078-0432.CCR-18-2814
- 475 20. Neel DS, Bivona TG. Resistance is futile: overcoming resistance to targeted therapies  
476 in lung adenocarcinoma. *npj Precis Oncol*. 2017;1(1):3. doi:10.1038/s41698-017-  
477 0007-0
- 478 21. Soria J-C, Lee H-Y, Lee JI, et al. Lack of PTEN expression in non-small cell lung  
479 cancer could be related to promoter methylation. *Clin Cancer Res*. 2002;8(5):1178-  
480 1184. <http://www.ncbi.nlm.nih.gov/pubmed/12006535>. Accessed April 23, 2019.
- 481 22. Aisner DL, Sholl LM, Berry LD, et al. The Impact of Smoking and TP53 Mutations in  
482 Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer  
483 Mutation Consortium (LCMC2). *Clin Cancer Res*. 2018;24(5):1038-1047.  
484 doi:10.1158/1078-0432.CCR-17-2289
- 485 23. Yoo SB, Xu X, Lee HJ, et al. Loss of PTEN Expression is an Independent Poor  
486 Prognostic Factor in Non-small Cell Lung Cancer. *Korean J Pathol*. 2011;45(4):329.  
487 doi:10.4132/KoreanJPathol.2011.45.4.329
- 488 24. VanderLaan PA, Rangachari D, Mockus SM, et al. Mutations in TP53 , PIK3CA ,

- 489 PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical  
490 outcomes. *Lung Cancer*. 2017;106:17-21. doi:10.1016/j.lungcan.2017.01.011
- 491 25. Sos ML, Koker M, Weir BA, et al. PTEN loss contributes to erlotinib resistance in  
492 EGFR-mutant lung cancer by activation of Akt and EGFR. *Cancer Res*.  
493 2009;69(8):3256-3261. doi:10.1158/0008-5472.CAN-08-4055
- 494 26. Takeda H, Takigawa N, Ohashi K, et al. Vandetanib is effective in EGFR-mutant lung  
495 cancer cells with PTEN deficiency. *Exp Cell Res*. 2013;319(4):417-423.  
496 doi:10.1016/j.yexcr.2012.12.018
- 497 27. Endoh H, Yatabe Y, Kosaka T, Kuwano H, Mitsudomi T. PTEN and PIK3CA  
498 expression is associated with prolonged survival after gefitinib treatment in EGFR-  
499 mutated lung cancer patients. *J Thorac Oncol*. 2006;1(7):629-634. doi:10.1016/S1556-  
500 0864(15)30374-9
- 501 28. Jing C, Mao X, Wang Z, et al. Next-generation sequencing-based detection of  
502 EGFR, KRAS, BRAF, NRAS, PIK3CA, Her2 and TP53 mutations in patients with  
503 non-small cell lung cancer. *Mol Med Rep*. 2018;18(2):2191-2197.  
504 doi:10.3892/mmr.2018.9210
- 505 29. Scheffler M, Bos M, Gardizi M, et al. &PIK3CA& mutations in non-small  
506 cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of  
507 prior malignancies. *Oncotarget*. 2015;6(2):1315-1326. doi:10.18632/oncotarget.2834
- 508 30. Engelman JA, Mukohara T, Zejnullahu K, et al. Allelic dilution obscures detection of a  
509 biologically significant resistance mutation in EGFR-amplified lung cancer. *J Clin  
510 Invest*. 2006;116(10):2695-2706. doi:10.1172/JCI28656
- 511 31. Sequist L V, Waltman BA, Dias-Santagata D, et al. Genotypic and histological  
512 evolution of lung cancers acquiring resistance to EGFR inhibitors. *Sci Transl Med*.  
513 2011;3(75):75ra26. doi:10.1126/scitranslmed.3002003

- 514 32. Ramalingam SS, Cheng Y, Zhou C, et al. LBA50Mechanisms of acquired resistance to  
515 first-line osimertinib: Preliminary data from the phase III FLAURA study. *Ann Oncol*.  
516 2018;29(suppl\_8). doi:10.1093/annonc/mdy424.063
- 517 33. Wu S-G, Chang Y-L, Yu C-J, Yang P-C, Shih J-Y. The Role of PIK3CA Mutations  
518 among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to  
519 EGFR Tyrosine Kinase Inhibition. *Sci Rep*. 2016;6(1):35249. doi:10.1038/srep35249
- 520 34. Eng J, Woo KM, Sima CS, et al. Impact of Concurrent PIK3CA Mutations on  
521 Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on  
522 Prognosis in Oncogene-Driven Lung Adenocarcinomas. *J Thorac Oncol*.  
523 2015;10(12):1713-1719. doi:10.1097/JTO.0000000000000671
- 524 35. Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14  
525 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to  
526 MET inhibitors. *Cancer Discov*. 2015;5(8):850-859. doi:10.1158/2159-8290.CD-15-  
527 0285
- 528 36. Suzawa K, Offin M, Lu D, et al. Activation of KRAS mediates resistance to targeted  
529 therapy in MET exon 14 mutant non-small cell lung cancer. *Clin Cancer Res*. October  
530 2018:clincanres.1640.2018. doi:10.1158/1078-0432.CCR-18-1640
- 531 37. Bahcall M, Awad MM, Sholl LM, et al. Amplification of wild type KRAS imparts  
532 resistance to crizotinib in MET exon 14 mutant non-small cell lung cancer. *Clin Cancer*  
533 *Res*. August 2018:clincanres.0876.2018. doi:10.1158/1078-0432.CCR-18-0876
- 534 38. Juric D, Rodon J, Tabernero J, et al. Phosphatidylinositol 3-Kinase  $\alpha$ -Selective  
535 Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the  
536 First-in-Human Study. *J Clin Oncol*. 2018;36(13):1291-1299.  
537 doi:10.1200/JCO.2017.72.7107
- 538 39. van den Bent M, Azaro A, Vos F, et al. ACTR-74. A PHASE IB/II, OPEN-LABEL,



539 MULTICENTER STUDY OF CAPMATINIB (INC280) ALONE AND IN COMBINATION  
540 WITH BUPARLISIB (BKM120) IN ADULT PATIENTS WITH RECURRENT  
541 GLIOBLASTOMA. *Neuro Oncol.* 2017;19(suppl\_6):vi16-vi17.  
542 doi:10.1093/neuonc/nox168.061

543 40. Mitiushkina N V, Kholmatov MM, Tiurin VI, et al. Comparative analysis of expression  
544 of mutant and wild-type alleles is essential for reliable PCR-based detection of MET  
545 exon 14 skipping. *Biochimie.* 2019;165:267-274. doi:10.1016/j.biochi.2019.08.014

546 41. Davies KD, Lomboy A, Lawrence CA, et al. DNA-Based versus RNA-Based Detection  
547 of MET Exon 14 Skipping Events in Lung Cancer. *J Thorac Oncol.* 2019;14(4):737-  
548 741. doi:10.1016/j.jtho.2018.12.020

549 42. Kim EK, Kim KA, Lee CY, et al. Molecular Diagnostic Assays and Clinicopathologic  
550 Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung Cancer. *Clin*  
551 *Lung Cancer.* 2019;20(1):e123-e132. doi:10.1016/j.clc.2018.10.004

552 43. Paik PK, Drilon A, Fan P-D, et al. Response to MET Inhibitors in Patients with Stage  
553 IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping.  
554 *Cancer Discov.* 2015;5(8):842-849. doi:10.1158/2159-8290.CD-14-1467

555

556

557

558 **Figure legends**

559 **Figure 1. Alterations in the PI3K pathway are common in *METex14* NSCLC. (A)**

560 Baseline characteristics of and treatments received by the patients with an advanced  
561 *METex14* non-small cell lung cancer. **(B)** Pie charts displaying the frequencies (%) of  
562 alterations of the examined genes in the cohort (n=65) and PTEN expression within  
563 each tumor sample tested by IHC (n=19). **(C)** Left panel (PTEN negative) shows  
564 undetectable PTEN in cancer cells of tumor specimen from patient CHUL#11 ; Right  
565 panel (PTEN positive) shows expression of PTEN in cancer cells of tumor specimen  
566 from patient CHUL#15. Thin arrows indicate cancer cells and large arrows indicate  
567 endothelial or immune cells (internal positive control). **(D)** Schematic presentation of  
568 patients according to the response to MET TKI treatment and to the presence or  
569 absence of a PI3K pathway alteration (n=17). Sub: substitution; Del : deletion; Indel :  
570 insertion-deletion **(E)** Computed tomography scans of CHUL#11, showing multiple  
571 lymph node metastases at baseline (upper left) and progression after two months of  
572 MET TKI treatment (upper right). Scans of CHUL#18, showing emergence of bone  
573 metastases after two months of MET TKI treatment (middle right panel). Lower  
574 abdomen scans of CHUL#20, showing lymph node metastases at baseline (lower  
575 left), which significantly increased after one month of MET TKI treatment (lower right  
576 panel).

577

578 **Figure 2. Patient-CHUL#11-derived cell line with PTEN loss shows sustained**

579 **activation of the PI3K pathway and resistance to MET TKI. (A)** Melting curve  
580 analysis of MET splicing isoforms and agarose gel electrophoresis of the amplicons  
581 generated by fluorescence reverse-transcription PCR. cDNA from cell lines

582 expressing a characterized MET-exon-14-skipping alteration (Hs746T, H596) or a  
583 wild-type MET (A549, PC9, GTL16) were used as controls. **(B)** Immunoblots for  
584 ZORG cells versus PTEN-expressing cell lines. Tubulin was used as a loading  
585 control. **(C)** ZORG cells were serum starved for 24 h and stimulated or not for 30 min  
586 with 50 ng/ml HGF. Cells were harvested and subjected to western blotting with the  
587 indicated antibodies. **(D)** The viability of ZORG cells in response to MET TKIs was  
588 assessed by MTT assay after 72 h of treatment. The sensitive Hs746T cell line was  
589 used as control. Results are presented as means  $\pm$  SEM of at least three  
590 independent experiments. **(E)** Serum-starved ZORG and Hs746T cells were treated  
591 for 30 min with each MET TKI at 1  $\mu$ M in the presence of HGF. Expression and  
592 activation of MET and its related signaling pathways were investigated by western  
593 blotting.

594

595 **Figure 3. PI3K inhibition restores sensitivity to MET TKIs in ZORG, a *METex14***  
596 **cell line with PTEN loss. (A)** Proliferation of ZORG cells treated with a MET TKI  
597 (capmatinib) at 0.5 or 1  $\mu$ M, a PI3K $\alpha/\delta$  inhibitor at 0.5 or 1  $\mu$ M (GDC0941), or both  
598 (each at 0.5 or 1  $\mu$ M) plus HGF at 20 ng/ml. IncuCyte® confluence measurements  
599 were performed every 4 h for 196 h. Results are presented as means  $\pm$  SEM of three  
600 independent experiments. Statistical significance was calculated with the Wilcoxon  
601 test. **(B)** Dose-response curve of ZORG cells treated for 3 days with capmatinib,  
602 GDC0941, or both and assessed by MTT assay. **(C)** ZORG cells were serum starved  
603 for 24 h and treated for 30 min with DMSO, 1  $\mu$ M capmatinib, 1  $\mu$ M GDC0941, or  
604 capmatinib plus GDC0941 (at 1  $\mu$ M each) and HGF at 50 ng/ml. Western blot  
605 analyses with the indicated antibodies were performed on cell lysates. Tubulin was  
606 used as loading control.

607

608 **Figure 4. Inhibition of PI3K restores sensitivity to a MET TKI in a *METex14* cell**  
609 **line with a *PIK3CA* mutation**

610 **(A)** Viability curves of H596 cells treated with increasing doses of MET TKI. Viability  
611 was assessed by MTT assay. IC<sub>50</sub> values were calculated with GraphPad Prism  
612 version 5.01, as the means of three independent experiments **(B)** IncuCyte® analysis  
613 of proliferation measured as confluence per well of H596 cells treated with DMSO,  
614 capmatinib, GDC0941, or capmatinib plus GDC0941 (each at 0.5 or 1 μM) and HGF  
615 at 20 ng/ml. Results are presented as means ± SEM of three independent  
616 experiments. Statistical significance was calculated with the Wilcoxon test. **(C)** MET  
617 expression and downstream signaling were investigated in H596 cell lines by western  
618 blotting. For 30 min before lysis, serum-starved cells were treated with each TKI  
619 alone and with both combined. **(D)** Dose-response curve of H596 cells treated for 3  
620 days with capmatinib, GDC0941, or both and assessed by MTT assay.

621 **Figure 5. *PIK3CA* mutations contribute to MET inhibitor resistance in *METex14***


622 **cells. (A)** IncuCyte® analysis of proliferation, measured as confluence per well, of  
623 T47D parental cells versus T47DMETex14 cells treated with DMSO, capmatinib,  
624 GDC0941, or capmatinib plus GDC0941 (at 0.5 or 1 μM each) and HGF at 20 ng/ml.  
625 Results are presented as means ± SEM of three independent experiments. Statistical  
626 significance was calculated with the Wilcoxon test. **(B)** MET expression and  
627 downstream signaling were investigated in T47D and T47DMETex14 cell lines by  
628 western blotting. For 30 min before lysis, serum-starved cells were treated with each  
629 TKI alone and with both combined. **(C)** Dose-response curve of T47DMETex14 cells  
630 treated for 3 days with capmatinib, GDC0941, or both and assessed by MTT assay.

Figure 1



A

	<b>n = 65</b>
Age, median (years) (range)	75 (49-88)
Male	33 (51%)
Female	32 (49%)
Adenocarcinoma	53 (80%)
Pulmonary sarcomatoid carcinoma	3 (6%)
Pleomorphic carcinoma	1 (2%)
Other	8 (12%)
Stage at diagnosis	<b>n=64</b>
Stage I-III	21 (33%)
Stage IV	43 (67%)
Tabac status	<b>n=64</b>
Current Smokers	4 (6%)
Former Smokers	25 (39%)
Never Smokers	35 (55%)
Treatment received (advanced stage)	<b>n=36</b>
Chemotherapy	23 (64%)
MET TKI	17 (47%)
Immunotherapy	9 (25%)


B




C







D



E





MET TKI	ZORG IC50 (μM)
Capmatinib	>10
Tepotinib	>10
Crizotinib	2.0 [1.45-2.75]
Foretinib	1.23 [0.83-1.82]

MET TKI	Hs746T IC50 (μM)
Capmatinib	0.003 [0.001-0.005]
Tepotinib	0.016 [0.01-0.03]
Crizotinib	0.032 [0.02-0.05]
Foretinib	0.027 [0.02-0.040]








Figure 3



MET TKI	ZORG IC50 (µM)
Capmatinib	>10
GDC0941	2.09 [1.77-2.47]
Capmatinib + GDC0941	0.034 [0.02-0.04]




Figure 4











Figure 5

A



B



C

